Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

999
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
999
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.3K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.3K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.8K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.8K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.4K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.4K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

701
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
701
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

922
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
922

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Rufinamide. A review of its pharmacokinetic and pharmacodynamic properties].

Revista de neurologia·2008
Same author

[Rational combination therapy in epilepsy. III. Possible associations between antiepileptic drugs].

Revista de neurologia·2007
Same author

[Rational combination therapy in epilepsy. II. Clinical and pharmacological aspects].

Revista de neurologia·2007
Same author

[Rational combination therapy in epilepsy. I. Concepts and foundations].

Revista de neurologia·2007
Same author

[Cognitive repercussion of early-onset epilepsies].

Revista de neurologia·2007
Same author

[Hypothalamic hamartoma: clinical characteristics. Electroencephalogram and brain magnetic resonance imaging in 10 patients].

Neurologia (Barcelona, Spain)·2007
Same journal

The Correlation Between and Variability of Three Balance Scales in the Assessment of Balance Function in Patients With Ataxia.

Revista de neurologia·2026
Same journal

Surgical Treatment of an Aneurysm in the Subacute Stage of Hemorrhagic Moyamoya Disease: Aneurysm Resection Combined With STA-MCA Bypass: A Case Report.

Revista de neurologia·2026
Same journal

Mapping the Evidence: Central Sleep Apnea Syndromes During Sleep and Stroke-A Scoping Review.

Revista de neurologia·2026
Same journal

Developmental and Epileptic Encephalopathy Due to a Novel <i>ARHGEF9</i> Deletion Variant: Case Series of Two Siblings.

Revista de neurologia·2026
Same journal

P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.

Revista de neurologia·2026
Same journal

[Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache].

Revista de neurologia·2026
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

[Antiepileptic drugs].

J L Herranz1

  • 1Universidad de Cantabria, 39011 Santander, Espana.

Revista De Neurologia
|June 8, 2018
PubMed
Summary
This summary is machine-generated.

New antiepileptic drugs, including eslicarbazepine acetate, brivaracetam, and perampanel, show notable pharmacokinetic and pharmacodynamic traits. Open-label trials reveal their real-world efficacy and safety profiles for epilepsy management.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K

Related Experiment Videos

Last Updated: Feb 9, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Neurology

Background:

  • Epilepsy treatment continually evolves with new antiepileptic drugs (AEDs).
  • Understanding the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of novel AEDs is crucial for optimizing patient outcomes.
  • Recent advancements include the introduction of eslicarbazepine acetate, brivaracetam, and perampanel.

Purpose of the Study:

  • To summarize the key pharmacokinetic and pharmacodynamic characteristics of recently commercialized antiepileptic drugs.
  • To analyze the efficacy and safety of eslicarbazepine acetate, brivaracetam, and perampanel based on open-label clinical trial data.
  • To provide insights into the real-world application of these new AEDs.

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic data for eslicarbazepine acetate, brivaracetam, and perampanel.
  • Analysis of efficacy and safety outcomes reported in open-label clinical trials.
  • Comparison of drug characteristics to inform clinical practice.

Main Results:

  • Eslicarbazepine acetate, brivaracetam, and perampanel exhibit distinct PK/PD profiles influencing their therapeutic use.
  • Open-label trials indicate a generally favorable efficacy and safety balance for these agents in diverse epilepsy populations.
  • Real-world data from open-label studies offer valuable insights beyond controlled trial settings.

Conclusions:

  • The pharmacokinetic and pharmacodynamic properties of eslicarbazepine acetate, brivaracetam, and perampanel are well-characterized.
  • Open-label trials provide a realistic assessment of the efficacy and safety of these newer antiepileptic drugs.
  • These findings support informed clinical decision-making for epilepsy treatment with recently approved AEDs.